Bookmark and Share

Julie A. Kreyenbuhl
 

Julie A. Kreyenbuhl Pharm.D., Ph.D.

Academic Title: Associate Professor
Primary Appointment: Psychiatry
jkreyenb@psych.umaryland.edu
Location: VA Annex, 735
Phone: 410-637-1864
Phone: 410-706-3211
Fax: 410-637-1880
 

Personal History:

Julie Kreyenbuhl, Pharm.D., Ph.D., is a Research Investigator and Associate Director of the Research Core for the VA VISN 5 Mental Illness Research, Education, and Clinical Center (MIRECC) and an Associate Professor of Psychiatry in the Division of Psychiatric Services Research, Department of Psychiatry, University of Maryland School of Medicine. Dr. Kreyenbuhl received a Pharm.D. from Mercer University College of Pharmacy and Health Sciences and a Ph.D. in Pharmaceutical Health Services Research from the University of Maryland School of Pharmacy. She also completed a post-doctoral fellowship at the Maryland Psychiatric Research Center.

Research Interests:

Dr. Kreyenbuhl's primary research interest is the pharmacoepidemiology of serious mental illness. She was the recipient of a K01 Research Career Award from NIMH that focused on prescription decision-making and patterns of use of complex, multidrug regimens in schizophrenia. Dr. Kreyenbuhl has contributed extensively to the development of evidence-based treatment guidelines for schizophrenia, serving as a co-investigator on the first update and principal investigator of grants funded by the NIMH and the VA to support the second update of the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. She also served as a consultant to the American Psychiatric Association during their last effort to update the Practice Guideline for the Treatment of Patients with Schizophrenia.

In addition, Dr. Kreyenbuhl has expertise in the area of medication adherence and has received support from the Brain and Behavior Research Foundation to evaluate adherence to antipsychotic and oral hypoglycemic medications in individuals with schizophrenia and Type 2 diabetes. She is also interested in methods to improve screening for the metabolic side effects of antipsychotic medications. She has received grant funding from VA HSR&D to determine if providing computerized, personalized health information directly to veterans with serious mental illnesses on whether their care adheres to screening guidelines for metabolic side effects increases rates of screening and activates patients to discuss screening with their providers.

She has also received grant funding from VA HSR&D to study how women Veterans with serious mental illnesses and their prescribers manage the metabolic side effects of psychotropic medications of which women are disproportionately affected. She is also the PI, Co-PI, or co-investigator on other funded efforts to study computer-technology based interventions for individuals with serious mental illnesses, including the development and testing of a Smartphone application for enhancing adherence to antipsychotic medications. Dr. Kreyenbuhl has authored or co-authored over 75 publications in peer-reviewed journals.


Publications:

Kreyenbuhl J, Record EJ, Palmer-Bacon J. A Review of Behavioral Tailoring Strategies for Improving Medication Adherence in Serious Mental Illness. In press, Dialogues in Clinical Neuroscience.

Charlotte M, Schwartz E, Slade E, Medoff D, Li L, Dixon L, Kilbourne AM, Kreyenbuhl J. Gender differences in mood stabilizer medications prescribed to veterans with serious mental illness. Journal of Affective Disorders 2015, 188, 112-117.

Schwartz E, Charlotte M, Slade E, Medoff D, Li L, Dixon L, Kilbourne A, Kreyenbuhl J. Gender Differences in Antipsychotics Prescribed to Veterans with Serious Mental Illness. General Hospital Psychiatry 2015; 37(4):347-51.

Record EJ, Medoff D, Dixon L, Klingaman E, Park S, Hack S, Brown C, Fang LJ, Kreyenbuhl J. Use of the internet among veterans with serious mental illness. Community Ment Health J. 2015 Mar 31. [Epub ahead of print] PubMed PMID: 25821927.

Klingaman EA, Medoff DR, Park SG, Brown CH, Fang L, Dixon LB, Hack S, Tapscott S, Walsh MB, Kreyenbuhl JA. Consumer satisfaction with psychiatric services: The role of shared decision-making and the therapeutic relationship. Psychiatric Rehabilitation Journal 2015 Feb 9. [Epub ahead of print] PubMed PMID: 25664755.

Essock SM, Nossel IR, McNamara K, Bennett ME, Buchanan RW, Kreyenbuhl JA, Mendon SJ, Goldman HH, Dixon LB. Practical Monitoring of Treatment Fidelity: Examples From a Team-Based Intervention for People With Early Psychosis. Psychiatr Serv. 2015 Jan 2:appips201400531.

Park SG, Derman M, Dixon LB, Brown CH, Klingaman EA, Fang LJ, Medoff DR, Kreyenbuhl J. Factors Associated With Shared Decision-Making Preferences Among Veterans With Serious Mental Illness. Psychiatric Services 2014; Dec 1;65(12):1409-13

Long JA, Wang A, Medvedeva EL, Eisen SV, Gordon A, Kreyenbuhl J, Marcus SC. Glucose Control and Medication Adherence Among Veterans With Diabetes and Serious Mental Illness: Does Collocation of Primary Care and Mental Health Care Matter? Diabetes Care 2014 Aug; 37:1(7).

Goldberg RW, Dickerson F, Lucksted A, Brown CH, Weber E, Tenhula WN, Kreyenbuhl J, Dixon LB. Living Well: An Intervention to Improve Self-Management of Medical Illness for Individuals With Serious Mental Illness. Psychiatr Serv. 2013; Jan;64(1):51-7.

Aakre JM, Medoff DR, Dixon LB, Kreyenbuhl J. Beliefs about antipsychotic versus hypoglycemic medications among individuals with serious mental illness and type 2 diabetes. Patient Prefer Adherence 2012; 6:389-94.

Kreyenbuhl J, Slade EP, Medoff DR, Brown CH, Ehrenreich B, Afful J, Dixon LB. Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia. . Schizophrenia Research 2011; 131(1-3):127-32.

Kreyenbuhl J, Leith J, Medoff DR, Fang L, Dickerson FB, Brown C, Goldberg RW, Potts W, Dixon LB. A comparison of adherence to hypoglycemic medications between type 2 diabetes patients with and without serious mental illness. Psychiatry Research 2011; 188: 109-114.

Kreyenbuhl J, Dixon LB, McCarthy JF, Soliman S, Ignacio RV, Valenstein M. Does adherence to medications for Type 2 diabetes differ between individuals with versus without schizophrenia? Schizophrenia Bulletin 2010; 36(2): 428-435.

Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009. Schizophr Bull 2010 Jan; 36(1):94-103.

Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. Schizophr Bull 2010 Jan; 36(1):71-93.

Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, Lehman A, Tenhula WN, Calmes C, Pasillas RM, Peer J, Kreyenbuhl J. The 2009 Schizophrenia PORT Psychosocial Treatment Recommendations and Summary Statements. Schizophr Bull 2010 Jan; 36(1):48-70.

Kreyenbuhl J, Nossel IR, Dixon LB. Disengagement from mental health treatment among individuals with schizophrenia and strategies for facilitating connections to care: A review of the literature. Schizophrenia Bulletin 2009; 35 (4):696-703.

Kreyenbuhl J, Medoff DR, Seliger SL, Dixon LB. Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes. Schizophrenia Research 2008; 101: 256-265.

Kreyenbuhl J, Marcus SC, West JC, Wilk J, Olfson M. Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatric Services 2007; 58(7): 983-990.